单位：[1]Chinese Acad Med Sci, Canc Hosp, Beijing, Peoples R China[2]Shandong First Med Univ, Affiliated Canc Hosp, Jinan, Peoples R China[3]Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Wuhan, Peoples R China华中科技大学同济医学院附属同济医院[4]Peking Univ Canc Hosp, Beijing, Peoples R China[5]Innovent Biol Inc, Suzhou, Peoples R China
第一作者单位：[1]Chinese Acad Med Sci, Canc Hosp, Beijing, Peoples R China
推荐引用方式(GB/T 7714)：
Wang Jie,Sun Yuping,Chu Qian,et al.Phase I study of IBI322 (anti-CD47/PD-L1 bispecific antibody) monotherapy therapy in patients with advanced solid tumors in China[J].CANCER RESEARCH.2022,82(12):
APA：
Wang, Jie,Sun, Yuping,Chu, Qian,Duan, Jianchun,Wan, Rui...&Wang, Yan.(2022).Phase I study of IBI322 (anti-CD47/PD-L1 bispecific antibody) monotherapy therapy in patients with advanced solid tumors in China.CANCER RESEARCH,82,(12)
MLA：
Wang, Jie,et al."Phase I study of IBI322 (anti-CD47/PD-L1 bispecific antibody) monotherapy therapy in patients with advanced solid tumors in China".CANCER RESEARCH 82..12(2022)
医学